Novartis AG (NYSE: NVS) is scheduled to report second-quarter earnings before the opening bell on Thursday, July 18. The Switzerland-based pharmaceutical giant
Search Results for: Novartis AG
Novartis’ one-time gene therapy for spinal muscular atrophy gets FDA nod
Picture Courtesy: Novartis Zolgensma, a gene-based treatment from Novartis (NYSE: NVS) for the treatment of spinal muscular atrophy that affects newborns, received
Novartis (NVS) stock falls after Alcon spin-off; predicts stable growth ahead
Nearly a year after laying out its transformation strategy, with focus on demerging underperforming business units, Novartis (NYSE: NVS) Tuesday said it
Amarin shares jump 14% on rumors over Novartis interest
Shares of Amarin Corp (AMRN) gained up to 14% during the regular trading hours on Friday as rumors of an acquisition once
Novartis stock rises on upbeat Q3 results
Novartis AG (NVS) reported a 22% dip in earnings for the third quarter due to charges from the voluntary withdrawal of CyPass,
Trump’s message doesn’t hurt Pfizer and other drugmakers
Right from his campaigning days, President Trump was slamming the US pharma companies for the high drug prices. In his first press
Adamis finally snags a marketing partner; All eyes on Mylan’s EpiPen
Shares of Adamis (ADMP) have been punched hard for several months due to the company’s inability to find a partner to commercialize
Novartis to demerge underperforming eyecare business Alcon
For the past few years, Novartis (NVS) has been concentrating more on the development of new drugs by bringing innovation and technology
Novartis-AveXis : A ‘gene’-ius deal?
Novartis AG is wagering high on gene therapy with its proposed acquisition of AveXis Inc. valued at $8.7 billion or $218 per
IPO Alert: Third Harmonic files to go public. Here’s what you need to know
IPO activity has started gaining steam after falling significantly in the first half, in line with the global trend, but it is
Earnings calendar for the week of July 19
Despite strong trading and encouraging news from the labor market, benchmark stock indexes pulled back after making modest gains early in the
Earnings calendar for the week of January 25
Leading stock indices continued the recent rally this week, with S&P 500 and Dow Jones Industrial Average setting new records helped mainly
Axsome Therapeutics stock climbs to 34-month high
After the slump on weak quarterly results, investors turned positive on Axsome Therapeutics (AXSM) stock, which climbed to the 34-month high of
European competition threatens AbbVie’s run of top-selling Humira
US pharma giant AbbVie Inc (ABBV) cut its overseas sales forecast on Friday for its offering Humira, on expected pricing cuts to
Johnson & Johnson (JNJ) Q3 2023 Earnings Call Transcript
Johnson & Johnson (NYSE: JNJ) Q3 2023 Earnings Call dated Oct. 17, 2023 Corporate Participants: Jessica Moore -- Vice President - Investor
Adobe Inc (ADBE) Q2 2023 Earnings Call Transcript
Adobe Inc (NASDAQ: ADBE) Q2 2023 earnings call dated Jun. 15, 2023 Corporate Participants: Jonathan Vaas -- Vice President of Investor Relations Shantanu Narayen -- Chairman
Amgen Inc. (AMGN) Q1 2023 Earnings Call Transcript
Amgen Inc. (NASDAQ: AMGN) Q1 2023 Earnings Call dated Apr. 27, 2023 Corporate Participants: Arvind Sood — Vice President, Investor Relations Robert A. Bradway — Chairman
Moderna Inc (MRNA) Q4 2022 Earnings Call Transcript
Moderna Inc (NASDAQ:MRNA) Q4 2022 Earnings Call dated Feb. 23, 2023. Corporate Participants: Lavina Talukdar -- Head of Investor Relations Stephane Bancel -- Chief Executive Officer
AstraZeneca PLC (AZN) Q4 2022 Earnings Call Transcript
AstraZeneca PLC (NYSE: AZN) Q4 2022 earnings call dated Feb. 09, 2023 Corporate Participants: Andy Barnett -- Vice President Global Head of Investor Relations Pascal
Merck & Co Inc (MRK) Q4 2022 Earnings Call Transcript
Merck & Co Inc (NYSE:MRK) Q4 2022 Earnings Call dated Feb. 02, 2023. Corporate Participants: Peter Dannenbaum -- Vice President, Investor Relations Robert M.
BioLife Solutions Inc. (BLFS) Q2 2022 Earnings Call Transcript
BioLife Solutions Inc. (NASDAQ: BLFS) Q2 2022 earnings call dated Aug. 09, 2022 Corporate Participants: Troy Wichterman -- Chief Financial Officer Michael Rice -- Chairman &